ATNX - ATNX STOCK NEWS

Athenex, a biopharmaceutical company focused on cancer therapies, announced that CEO Johnson Lau and Senior Director Daniel Lang will present at the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021, at 3:55 PM ET. A live audio webcast will be available on Athenex's website for 90 days after the event.

The company, founded in 2003, specializes in oncology and has several core technologies, including Orascovery and cell therapy.

Athenex (NASDAQ: ATNX) announced a licensing agreement with the National Cancer Institute (NCI) to expand its allogeneic NKT cell research and development pipeline targeting solid tumors. This agreement grants Athenex worldwide rights to develop and commercialize T cell receptor (TCR) based products using unique antigens from common mutations in genes like p53, KRAS, and EGFR. The deal is expected to increase market opportunities for treating solid tumors, potentially reaching over 100,000 new patients annually in the U.S.

Athenex, Inc. (NASDAQ: ATNX) announced encouraging results from the ANCHOR Phase 1 study on KUR-502, an allogeneic CD19 CAR-NKT cell therapy for B-cell malignancies. Among five patients treated, there were two partial responses, one complete response with incomplete hematological recovery, and one complete response. The therapy showed a favorable safety profile, with mainly nausea and mild cytokine release as side effects. The company plans to continue the study at higher doses and expand patient enrollment to further assess KUR-502's efficacy.

Athenex, Inc. (NASDAQ: ATNX) reported third quarter 2021 results with product sales of $27.0 million, a 9% increase year-over-year. However, the company anticipates a 6-12% decline in full-year product sales revenue compared to 2020, citing challenges in supply chains due to COVID-19. A Type A meeting with the FDA regarding oral paclitaxel led to a strategic shift towards ongoing clinical programs. Key updates include positive interim trial data and the launch of Klisyri in Europe. Cash and equivalents stood at $105 million as of September 30, 2021, prompting cash conservation measures.

Athenex (NASDAQ: ATNX) has announced a corporate and financial update for the third quarter of 2021, scheduled for November 4, 2021. The update will be accompanied by a conference call at 10:00 a.m. ET, allowing investors to engage with management. Participants can join via specific dialing numbers or through a live audio webcast available on the company’s Investor Relations website.

Athenex focuses on developing innovative cancer treatments and operates through three platforms aimed at enhancing drug commercial viability.

Athenex (NASDAQ: ATNX) announced a corporate and financial update for the third quarter of 2021, scheduled for November 5, 2021, before market opening. The management will host a conference call at 8:00 AM ET. Interested participants can join by dialing in or accessing the live audio webcast. Athenex focuses on developing and commercializing cancer therapies through its Oncology Innovation Platform, Commercial Platform, and Global Supply Chain Platform. The company aims to enhance cancer treatment options and patient outcomes.

Athenex (NASDAQ: ATNX) has received U.S. patent allowance for its NKT cell therapy platform, enhancing its position in oncology. This patent relates to genetically modified CD62L-positive human NKT cells with chimeric antigen receptors (CAR). Dr. Leonid Metelitsa highlighted that these modified NKT cells demonstrate durable antitumor responses in pre-clinical trials. The company is advancing clinical programs KUR-501 and KUR-502, targeting high-risk neuroblastoma and other malignancies. Athenex anticipates this patent will reinforce its leadership in NKT cell therapy, with over 100 patent applications pending globally.

Athenex (NASDAQ: ATNX) held a Type A meeting with the FDA to discuss the New Drug Application for oral paclitaxel and encequidar in metastatic breast cancer. The meeting aimed to evaluate a proposed redesign of a clinical trial following a Complete Response Letter received in February 2021. CEO Dr. Johnson Lau stated that the company would focus on other ongoing studies and therapies to optimize stakeholder value. Athenex remains dedicated to supporting patients through its specialty pharmaceutical business.

Athenex has announced the launch of Klisyri® (tirbanibulin) for treating actinic keratosis in Germany and the UK. This medication, approved by the European Commission and the UK’s MHRA, offers a short treatment duration of five days with good efficacy and tolerability. Athenex is set to receive up to $45M in milestone payments from its partner Almirall and will earn tiered royalties starting at 15% on annual net sales. The company is also expanding partnerships for Klisyri in additional regions including Australia, Japan, Taiwan, and China.